Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Rohrberg, Kristoffer Staala; c; * | Skov, Birgit Guldhammerb | Lassen, Ulrika | Christensen, Ib Jarlec | Høyer-Hansen, Gunillac | Buysschaert, Iand; e | Pappot, Hellea
Affiliations: [a] Department of Oncology, The Finsen centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark | [b] Department of Pathology, Herlev University Hospital, Copenhagen, Denmark | [c] The Finsen Laboratory, The Finsen centre, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark | [d] Vesalius Research Centre, VIB, Leuven, Belgium | [e] Vesalius Research Centre, K.U. Leuven, Leuven, Belgium
Correspondence: [*] Corresponding author: Kristoffer Staal Rohrberg, M.D., Ph.D., Department of Oncology, 5073, The Finsen Center, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. Tel.: +45 35451129; Fax: +45 35454391; E-mail: [email protected].
Abstract: The epidermal growth factor receptor (EGFR) and angiogenesis are well established targets in anti-cancer therapy. Several targeted anti-cancer therapies are in clinical trials in pancreatic and gastroesophageal (GEJ) cancer. However, many patients do not respond to these targeted therapies and there is therefore an increasing need for biomarkers for selection of patients to these therapies. We investigated the expression of EGFR, vascular endothelial growth factor A (VEGF-A), and VEGF receptor 2 (VEGFR-2) in tumour tissue by immunohistochemistry, and soluble EGFR (sEGFR), soluble VEGFR-2 (sVEGFR-2), basic fibroblast growth factor (bFGF), placental growth factor (PlGF), plasminogen activator inhibitor 1 (PAI-1), and different forms of the urokinase plasminogen activator receptor (uPAR): uPAR (I), uPAR (I–III), and uPAR (I–III)+(II–III) in plasma by quantitative immunoassays in 14 patients with pancreatic and GEJ cancer. We found expression in tumour tissue and the plasma levels to be similar to those found in patients with other tumour types. No correlation was found between the blood levels of soluble receptors and the corresponding tumour tissue levels. We conclude that these markers are present in pancreatic and GEJ cancer patients, and could be investigated further as predictive biomarkers in such patients treated with EGFR or angiogenesis targeted therapies.
Keywords: Angiogenesis, epidermal growth factor receptor, pancreatic cancer, gastroesophageal junction cancer
DOI: 10.3233/CBM-2010-0157
Journal: Cancer Biomarkers, vol. 7, no. 3, pp. 141-151, 2010
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]